Cerevance, a British clinical-stage biotech working on new medicines for brain disorders, has inked a deal with Merck & Co (NYSE: MRK), focused on Alzheimer’s disease.
The multi-year strategic research pact will see the firms collaborating with the goal of finding new targets using Cerevance’s proprietary technology.
While the approval of Aduhelm (aducanumab) has somewhat reinforced the value of the leading scientific paradigm in Alzheimer’s, targeting amyloid beta in the brain is yet to yield a comprehensive breakthrough in tackling the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze